Talking About Tumors

Chapter 2

Chapter 2: Breast Cancer

Early breast cancer, endocrine therapy, HER2-positive disease, triple-negative breast cancer, hereditary risk, and metastatic management.

← Back to episode archive

S02 E01

An Overview of Considerations for Early Breast Cancer

Open episode on Buzzsprout

Show notes

Topics covered

  1. History of surgery and radiation for breast cancer
  2. Indication and goal of adjuvant systemic therapy (incl cell-kill hypothesis)
  3. Overview of breast cancer subtypes
  4. Strategies and guidelines for surveillance
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations at your region of training.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Bonadonna G, et al. N Engl J Med. 1976;294(8):405-410. doi:10.1056/NEJM197602192940801
  2. 2. Giuliano AE, et al. JAMA. 2017;318(10):918-926. doi:10.1001/JAMA.2017.11470
  3. 3. Abe O et al. Lancet. 2005;365(9472):1687-1717. doi:10.1016/S0140-6736(05)66544-0
  4. 4. Albain K et al. The Lancet. 2012;379(9814):432-444. doi:10.1016/S0140-6736(11)61625-5
  5. 5. Asselain B et al. Lancet Oncol. 2018;19(1):27-39. doi:10.1016/S1470-2045(17)30777-5
  6. 6. Predict Breast. Accessed September 25, 2022. https://breast.predict.nhs.uk/
  7. 7. Masuda N et al. NEJM. 2017;376(22):2147-2159. doi:10.1056/NEJMOA1612645
  8. 8. Berruti A et al J Clin Oncol. 2014;32(34):3883-3891. doi:10.1200/JCO.2014.55.2836
  9. 9. von Minckwitz G et al. J Clin Oncol. 2012;30(15):1796-1804. doi:10.1200/JCO.2011.38.8595
  10. 10. Henry NL et al. J Clin Oncol. 2019;37(22):1965-1977. doi:10.1200/JCO.19.00948
  11. 11. von Minckwitz G et al. NEJM. 2019;380(7):617-628. doi:10.1056/NEJMOA1814017
  12. 12. Mukherjee Siddhartha. The emperor of all maladies : a biography of cancer. Published 2010.
  13. 13. Harris LN et al. J Clin Oncol. 2016;34(10):1134-1150. doi:10.1200/JCO.2015.65.2289
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S02 E02

Chemotherapy Options and Bisphosphonates in Early Breast Cancer

Open episode on Buzzsprout

Show notes

Topics covered

  1. First, second, and third generation chemotherapy regimens
  2. Considerations for anthracyclines
  3. Considerations for taxanes
  4. Adjuvant bisphosphonates
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Budd GT et al. J Clin Oncol. 2015;33(1):58-64. doi:10.1200/JCO.2014.56.3296
  2. 2. Citron ML et al. J Clin Oncol. 2003;21(8):1431-1439. doi:10.1200/JCO.2003.09.081
  3. 3. Anampa J, Makower D, Sparano JA. BMC Med. 2015;13(1). doi:10.1186/S12916-015-0439-8
  4. 4. Sparano JA et al. J Clin Oncol. 2015;33(21):2353-2360. doi:10.1200/JCO.2015.60.9271
  5. 5. Coleman R et al. Lancet. 2015;386(10001):1353-1361. doi:10.1016/S0140-6736(15)60908-4
  6. 6. Gray R et al. Lancet. 2019;393(10179):1440-1452. doi:10.1016/S0140-6736(18)33137-4
  7. 7. Abe O et al. Lancet. 2005;365(9472):1687-1717. doi:10.1016/S0140-6736(05)66544-0
  8. 8. Albain K et al. Lancet. 2012;379(9814):432. doi:10.1016/S0140-6736(11)61625-5
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S02 E03

Adjuvant endocrine therapy for early breast cancer

Open episode on Buzzsprout

Show notes

Topics covered

  1. Tamoxifen, its development, mechanism and benefits
  2. Aromatase inhibitors and their benefit in post-menopausal state
  3. Nuances on extended therapy beyond 5 years
  4. SOFT/TEXT, a broad overview of a complex publucation
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Pagani O et al.. NEJM. 2014;371(2):107-118. doi:10.1056/NEJMOA1404037
  2. 2. Francis PA et al. NEJM. 2018;379(2):122-137. doi:10.1056/NEJMOA1803164
  3. 3. Gnant M et al. NEJM. 2021;385(5):395-405. doi:10.1056/NEJMOA2104162
  4. 4. Cuzick J et al. Lancet Oncol. 2010;11(12):1135-1141. doi:10.1016/S1470-2045(10)70257-6
  5. 5. Regan MM et al. Lancet Oncol. 2011;12(12):1101-1108. doi:10.1016/S1470-2045(11)70270-4
  6. 6. Davies C et al.. The Lancet. 2013;381(9869):805-816. doi:10.1016/S0140-6736(12)61963-1
  7. 7. Goss PE et al. NEJM. 2016;375(3):209-219. doi:10.1056/NEJMOA1604700
  8. 8. Goss PE et al. J Natl Cancer Inst. 2005;97(17):1262-1271. doi:10.1093/JNCI/DJI250
  9. 9. Abe O et al. The Lancet. 2011;378(9793):771-784. doi:10.1016/S0140-6736(11)60993-8
  10. 10. Jordan VC. A Breast Cancer Research. 2003;5(6):294. doi:10.1186/BCR656
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S02 E04

Recurrence risk scores and CDK inhibitors for Early Breast Cancer

Open episode on Buzzsprout

Show notes

Topics covered

  1. Recurrence Risk Scores
  2. TailorRx, RxPonder, MINDACT Trials Overview
  3. Introduction to CDK 4/6 inhibitors
  4. PALLAS and MONARCH-E Discussion
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Johnston SRD et al. JCO. 2020;38(34):3987-3998. doi:10.1200/JCO.20.02514
  2. 2. Harbeck N et al. Ann Oncol. 2021;32(12):1571-1581. doi:10.1016/J.ANNONC.2021.09.015
  3. 3. Mayer EL et al. Lancet Oncol. 2021;22(2):212-222. doi:10.1016/S1470-2045(20)30642-2
  4. 4. Cardoso F et al. NEJM. 2016;375(8):717-729. doi:10.1056/NEJMOA1602253
  5. 5. Kalinsky K et al. NEJM. 2021;385(25):2336-2347. doi:10.1056/NEJMOA2108873
  6. 6. Sparano JA et al. NEJM. 2019;380(25):2395-2405. doi:10.1056/NEJMOA1904819
  7. 7. Paik S et al. JCO. 2006;24(23):3726-3734. doi:10.1200/JCO.2005.04.7985
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S02 E05

Management of Metastatic Hormone Positive Breast Cancer

Open episode on Buzzsprout

Show notes

Topics covered

  1. Endocrine Resistance: Definition and Mechanism
  2. Role of AI with and without CDK4/6 inhibitors
  3. Later line management of metastatic disease
  4. Informative Censoring and the BOLERO-2 trial
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Tannock I et al. Ann Oncol. 2020;31(3):331-333. doi:10.1016/J.ANNONC.2019.11.017
  2. 2. André F et al. NEJM. 2019;380(20):1929-1940. doi:10.1056/NEJMOA1813904
  3. 3. Tannock IF et al.. Annals of Oncology. 2014;25(10):2096. doi:10.1093/annonc/mdu371
  4. 4. Piccart M et al. Ann Oncol. 2014;25(12):2357-2362. doi:10.1093/ANNONC/MDU456
  5. 5. Baselga J et al. NEJM. 2012;366(6):520-529. doi:10.1056/NEJMOA1109653
  6. 6. Gao JJ et al. Lancet Oncol. 2020;21(2):250-260. doi:10.1016/S1470-2045(19)30804-6
  7. 7. Howie LJ et al. JCO. 2019;37(36):3475-3483. doi:10.1200/JCO.18.02217
  8. 8. Im SA et al. NEJM. 2019;381(4):307-316. doi:10.1056/NEJMOA1903765
  9. 9. Hortobagyi GN et al. NEJM. 2022;386(10):942-950. doi:10.1056/NEJMOA2114663
  10. 10. Finn RS et al. NEJM. 2016;375(20):1925-1936. doi:10.1056/NEJMOA1607303
  11. 11. Turner NC et al. NEJM. 2018;379(20):1926-1936. doi:10.1056/NEJMOA1810527
  12. 12. Robertson JFR et al. Lancet. 2016;388(10063):2997-3005. doi:10.1016/S0140-6736(16)32389-3
  13. 13. Mauri D et al. J Natl Cancer Inst. 2006;98(18):1285-1291. doi:10.1093/JNCI/DJJ357
  14. 14. Lindström LS et al. JCO. 2012;30(21):2601-2608. doi:10.1200/JCO.2011.37.2482
  15. 15. Mouridsen H et al. JCO. 2001;19(10):2596-2606. doi:10.1200/JCO.2001.19.10.2596
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S02 E06

HER-2 Low Breast Cancer and Sacituzumab Govitecan

Open episode on Buzzsprout

Show notes

Topics covered

  1. HER-2 Low Breast Cancer and Sacituzumab Govitecan
  2. HER-2 Testing Algorithm
  3. Trastuzumab Deruxtecan in HER-2 Low MBC
  4. 2:1 Randomization, Treatment of Provider Choice
  5. Sacituzumab Govitecan for later line TNBC and HR positive MBC
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Wolff A et al. JCO. 2018;36(20):2105-2122. doi:10.1200/JCO.2018.77.8738
  2. 2. Modi S et al. NEJM. 2022;387(1):9-20. doi:10.1056/NEJMOA2203690
  3. 3. BardiaI A et al. NEJM. 2021;384:1529-1541. doi:10.1056/NEJMOA2028485
  4. 4. Rugo H et al. JCO. Published online Aug 26, 2022 . doi:10.1200/JCO.22.01002
  5. 5. Rugo H et al. Ann Oncol. 2022;33(suppl_7):S808-S869. doi:10.1016/annonc/annonc1089
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S02 E07

HER-2 positive breast cancer: Considerations in advanced disease

Open episode on Buzzsprout

Show notes

Topics covered

  1. Anti-HER2 agent classes
  2. Cleopatra Trial
  3. Later line options
  4. Leptomeningeal carcinomatosis
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Dawood S et al. NEJM. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101
  2. 3. Baselga J et al. NEJM. 2012;366(2):109-119. doi:10.1056/NEJMOA1113216
  3. 4. Swain SM et al. NEJM. 2015;372(8):724-734. doi:10.1056/NEJMOA1413513
  4. 5. Verma S et al. T. NEJM. 2012;367(19):1783-1791. doi:10.1056/NEJMOA1209124
  5. 6. Cortés J et al. NEJM. 2022;386(12):1143-1154. doi:10.1056/NEJMOA2115022
  6. 7. Krop IE et al. Lancet Oncol. 2017;18(6):743-754. doi:10.1016/S1470-2045(17)30313-3
  7. 8. Murthy RK et al. NEJM. 2020;382(7):597-609. doi:10.1056/NEJMOA1914609
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S02 E08

Early HER-2 positive breast cancer

Open episode on Buzzsprout

Show notes

Topics covered

  1. Role of adjuvant HER-2 Agents and during of therapy
  2. Chemotherapy backbone considerations
  3. Pathologic complete response
  4. Neoadjuvant systemic therapy and response modified approach
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. von Minckwitz G et al. NEJM. 2019;380(7):617-628. doi:10.1056/NEJMOA1814017
  2. 2. von Minckwitz G et al. Adjuvant NEJM. 2017;377(2):122-131. doi:10.1056/NEJMOA1703643
  3. 3. Slamon D et al.. NEJM. 2011;365(14):1273-1283. doi:10.1056/NEJMOA0910383
  4. 4. Piccart M et al. JCO. 2021;39(13):1448-1457. doi:10.1200/JCO.20.01204
  5. 5. Martin M et al. Lancet Oncol. 2017;18(12):1688-1700. doi:10.1016/S1470-2045(17)30717-9
  6. 6. von Minckwitz G et al. NEJM. 2019;380(7):617-628. doi:10.1056/NEJMOA1814017
  7. 7. Gianni L et al. Lancet Oncol. 2014;15(6):640-647. doi:10.1016/S1470-2045(14)70080-4
  8. 8. Symmans WF et al.. J Clin Oncol. 2017;35(10):1049-1060. doi:10.1200/JCO.2015.63.1010
  9. 9. Gianni L et al. Lancet Oncol. 2016;17(6):791-800. doi:10.1016/S1470-2045(16)00163-7
  10. 10. Gianni L et al. Lancet Oncol. 2012;13(1):25-32. doi:10.1016/S1470-2045(11)70336-9
  11. 11. Gilboa S et al. Eur J Cancer. 2021;153:190-202. doi:10.1016/J.EJCA.2021.04.044
  12. 12. Tolaney SM et al. NEJM. 2015;372(2):134-141. doi:10.1056/NEJMOA1406281
  13. 13. Cameron D et al. Lancet. 2017;389(10075):1195-1205. doi:10.1016/S0140-6736(16)32616-2
  14. 14. Earl HM et al. Lancet. 2019;393(10191):2599-2612. doi:10.1016/S0140-6736(19)30650-6
  15. 15. Pivot X et al. Lancet. 2019;393(10191):2591-2598. doi:10.1016/S0140-6736(19)30653-1
  16. 16. Perez EA et al. J Clin Oncol. 2014;32(33):3744-3752. doi:10.1200/JCO.2014.55.5730
  17. 17. Romond EH et al. NEJM. 2005;353(16):1673-1684. doi:10.1056/NEJMOA052122
  18. 18. Ennis S et al.. NEJM. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101
  19. 19. Hudis CA. NEJM. 2007;357(1):39-51. doi:10.1056/NEJMRA043186
  20. 20. Slamon DJ et al. Science. 1987;235(4785):182-191. doi:10.1126/SCIENCE.3798106
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S02 E09

Triple Negative Breast Cancer

Open episode on Buzzsprout

Show notes

Topics covered

  1. Clinical considerations
  2. Neoadjuvant and adjuvant regimens
  3. Immunotherapy in localized and metastatic disease
  4. Later line options in metastatic setting
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Masuda N et al. NEJM. 2017;376(22):2147-2159. doi:10.1056/NEJMOA1612645
  2. 2. Zaheed M et al. Cochrane. 2019;2019(2). doi:10.1002/14651858.CD012873.PUB2/
  3. 3. Cortes J et al. The Lancet. 2020;396(10265):1817-1828. doi:10.1016/S0140-6736(20)32531-9
  4. 4. Cortes J et al. NEJM. 2022;387(3):217-226. doi:10.1056/NEJMOA2202809
  5. 5. Miles D et al. Ann Oncol. 2021;32(8):994-1004. doi:10.1016/j.annonc.2021.05.801
  6. 6. Emens LA et al. Ann Oncol. 2021;32(8):983-993. doi:10.1016/j.annonc.2021.05.355
  7. 7. Schmid P et al. NEJM. 2022;386(6):556-567. doi:10.1056/NEJMOA2112651
  8. 8. Schmid P et al. NEJM. 2020;382(9):810-821. doi:10.1056/NEJMOA1910549
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

S02 E10

BRCA Positive Breast Cancer in the Clinic

Open episode on Buzzsprout

Show notes

Topics covered

  1. BRCA 1/2 genes and relation to malignancy
  2. Family history taking and identifying patients for genetic testing
  3. Risk reduction strategies for breast and ovarian cancer
  4. Systemic therapy considerations in BRCA positive breast cancer
References and source notes

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

  1. 1. Litton JK et al. NEJM. 2018;379(8):753-763. doi:10.1056/NEJMOA1802905
  2. 2. Geyer CE et al. Ann Oncol. 2022;33(12):1250-1268. doi:10.1016/j.annonc.2022.09.159
  3. 3. Robson M et al. NEJM. 2017;377(6):523-533. doi:10.1056/NEJMOA1706450
  4. 4. Tutt ANJ et al. NEJM. 2021;384(25):2394-2405. doi:10.1056/NEJMOA2105215
  5. 5. Risk Reduction and Screening of Cancer in Hereditary Breast-Ovarian Cancer Syndromes | ESMO. Accessed March 13, 2023. https://www.esmo.org/guidelines/guidelines-by-topic/hereditary-syndromes/risk-reduction-screening-hereditary-breast-ovarian-cancer-syndromes
  6. 6. Breast Cancer Screening for Women at High Risk – Cancer Care Ontario. Accessed March 13, 2023. https://www.cancercareontario.ca/en/guidelines-advice/cancer-continuum/screening/breast-cancer-high-risk-women
  7. 7. Chiarelli AM et al. JCO. 2014;32(21):2224-2230. doi:10.1200/JCO.2013.52.8331
  8. 8. Detection, Prevention, and Risk Reduction. Accessed March 13, 2023. https://www.nccn.org/guidelines/category_2
Disclosure and tags

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags: Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology